Table 3.
Characteristic clinical and immunophenotypic features of various types of CTCL
| Clinical features | T-cell phenotype | Cytotoxic proteins | CD56 | Major lineage | EBV | |
|---|---|---|---|---|---|---|
| MF | Patches and plaques; (ulcerating) tumors in advanced stage | CD3+, CD4+, CD8− | − | − | αβ T cell | − |
| C-ALCL | Solitary or localized nodules or tumors | CD3+/−, CD4+, CD8−, CD30+ | + | − | αβ T cell | − |
| SPTCL | Subcutaneous nodules and plaques | CD3+, CD4−, CD8+ | + | − | αβ T cell | − |
| PCGD-TCL | Ulcerating plaques and tumors | CD3+, CD4−, CD8−/+ | + | + | γδ T cell | − |
| Extranodal NK/T-cell lymphoma | (Ulcerating) plaques and tumors | CD3+, CD4−, CD8+ (surface CD3−) | + | + | NK or γδ T cell | + |
| CD8+ AECTCL | Ulcerating plaques, nodules, and tumors | CD3+, CD4−, CD8+ | + | − | αβ T cell | − |
| Primary cutaneous acral CD8+ T-cell lymphoma | Solitary papule or nodule on acral site (ear; nose) | CD3+, CD4−, CD8+ | +/−* | − | αβ T cell | − |
| Primary cutaneous CD4+ small/medium T-cell LPD | Solitary nodule or tumor on the face or upper trunk | CD3+, CD4+, CD8−, CD279/PD-1+ | − | − | αβ T cell | − |
PCGD-TCL, primary cutaneous γ/δ T-cell lymphoma; SPTCL, subcutaneous panniculitis-like T-cell lymphoma.
*
Expresses a nonactivated cytotoxic phenotype, positive for TIA-1, but negative for other cytotoxic proteins.